WO2021062212A4 - Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same - Google Patents

Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same Download PDF

Info

Publication number
WO2021062212A4
WO2021062212A4 PCT/US2020/052805 US2020052805W WO2021062212A4 WO 2021062212 A4 WO2021062212 A4 WO 2021062212A4 US 2020052805 W US2020052805 W US 2020052805W WO 2021062212 A4 WO2021062212 A4 WO 2021062212A4
Authority
WO
WIPO (PCT)
Prior art keywords
asf
virus particles
naturally expressed
viral components
asfv
Prior art date
Application number
PCT/US2020/052805
Other languages
French (fr)
Other versions
WO2021062212A1 (en
Inventor
Huan Huu NGUYEN
Original Assignee
Igy Immune Technologies And Life Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igy Immune Technologies And Life Sciences Inc. filed Critical Igy Immune Technologies And Life Sciences Inc.
Priority to CN202080080011.9A priority Critical patent/CN114746110A/en
Publication of WO2021062212A1 publication Critical patent/WO2021062212A1/en
Publication of WO2021062212A4 publication Critical patent/WO2021062212A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides a method of isolating and preparing live African Swine Fever (ASF) viruses (ASFV) and an ASFV vaccine composed of whole ASF virus particles, viral components, and/or immunosuppressive protein factors. The ASFV vaccine can be used to immunize pigs and wild boars, or can be used to immunize species other than pig or wild boar, such as fowl, bovine, goat, rabbit, donkey or horse, to generate polyclonal immunoglobulins with broad-spectrum specificity to the ASFV. The ASFV-specific immunoglobulins then can be extracted and purified. The ASFV-specific immunoglobulins can provide acute treatment of ASF-infected pigs or wild boars or preventative treatment for pigs or wild boars at risk of ASF, for example that may have been exposed to ASFV or ASFV-infected subjects.

Claims

AMENDED CLAIMS received by the International Bureau on 26 April 2021 (26.04.2021)
Claim 1 : A method of treating African swine fever (ASF) viral (ASFV) infection in an infected pig or wild boar, the method comprising administering to the infected pig or wild boar an effective amount of a composition comprising IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors.
Claim 2: The method of Claim 1, wherein the composition is administered in an amount that provides a dose of the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors that is about 0.5 mg to about 1.0 mg per kg body weight of the infected pig or wild boar.
Claim 3 : The method of Claim 1 , wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is administered for a time period comprising at least once per week or 7 consecutive days.
Claim 4: The method of Claim 1, wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is administered parenterally by intramuscular or intraperitoneal injection.
Claim 5: The method of Claim 1, wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is a food product administered orally.
Claim 6: A method of preventing, decreasing incidence of, and/or decreasing severity of ASF viral infection in a pig or wild boar at risk thereof, the method comprising administering to the pig or wild boar an effective amount of a composition comprising IgY immunoglobulins
36 specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors.
Claim 7: The method of Claim 6, wherein the composition is administered in an amount that provides a dose of the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors that is about 0.5 to about 1.0 mg per kg of body weight of the pig or wild boar at risk thereof.
Claim 8: The method of Claim 6, wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is administered for a time period comprising at least once per week or 7 consecutive days.
Claim 9: The method of Claim 6, wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is administered parenterally.
Claim 10: The method of Claim 6, wherein the composition comprising the IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors is a food product administered orally.
Claim 11: A method of producing ASFV-specific immunoglobulins wherein a ASFV vaccine comprised of whole live ASF virus particles, naturally expressed ASF viral components, and/or immunosuppressive protein factors, is administered to a non-swine species host for ASFV-specific immunoglobulin production.
Claim 12: The method of Claim 11, wherein the host is an egg-laying fowl.
Claim 13: A unit dosage form comprising a therapeutically or prophylactically effective amount of a composition comprising IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors. Claim 14: The unit dosage form of Claim 13, wherein the composition is a food product formulated for oral administration.
Claim 15: A method of preventing, decreasing incidence of, and/or decreasing severity of ASF viral infection in a pig or wild boar at risk thereof, the method comprising administering to the pig or wild boar an effective amount of an ASFV vaccine composition comprising (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors.
Claim 16: The method of Claim 15, wherein the naturally expressed ASF viral components and whole live ASF virus particles are inactiv[e]ated using gamma irradiation.
Claim 17: The method of Claim 15, wherein the ASFV vaccine composition is administered parenterally by intramuscular or intraperitoneal injection.
Claim 18: The method of Claim 15, wherein the ASFV vaccine composition is administered in an amount that provides a dose of the naturally expressed ASF viral components that is about 0.05 mg to about 1.0 mg per pig or wild boar.
Claim 19: A unit dosage form comprising an effective amount of an ASFV vaccine composition comprising naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors.
Claim 20: The unit dosage form of Claim 19, wherein the naturally expressed ASF viral components and whole live ASF virus particles are derived from ASF-infected spleen mononuclear cells (SMNCs), ASF-infected peripheral blood and mononuclear cells (PBMCs), and/or ASF-infected primary alveolar macrophages (PAMs).
Claim 21: The unit dosage form of Claim 19, wherein the naturally expressed ASF viral components are inactivated using gamma irradiation.
Claim 22: ASFV vaccine, comprising IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors for use in the treatment and/or prevention of ASF infection in a pig or wild boar at risk thereof. Claim 23: A composition comprising IgY immunoglobulins specific against (a) naturally expressed ASF viral components, (b) whole live ASF virus particles, and/or (c) immunosuppressive protein factors for use in the treatment and/or prevention of ASF infection in a pig or wild boar at risk thereof.
Claim 24: The method of Claim 1, wherein the naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors are derived from cells, tissues, and/or organs of an ASFV-infected pig or wild boar.
Claim 25: The method of Claim 1, wherein the naturally expressed ASF viral components and whole live ASF virus particles are inactivated by gamma irradiation.
Claim 26: The method of Claim 6, wherein the naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors are derived from cells, tissues, and/or organs of an ASFV-infected pig or wild boar.
Claim 27: The method of Claim 11, wherein the naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors are derived from cells, tissues, and/or organs of an ASFV-infected pig or wild boar.
Claim 28: The method of Claim 13, wherein the naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors are derived from cells, tissues, and/or organs of an ASFV-infected pig or wild boar.
Claim 29: The method of Claim 13, wherein the naturally expressed ASF viral components and whole live ASF virus particles are inactivated by gamma irradiation.
Claim 30: The unit dosage form of Claim 19, wherein the naturally expressed ASF viral components, whole live ASF virus particles, and/or immunosuppressive protein factors are derived from ASF-infected spleen mononuclear cells (SMNCs) and/or ASF-infected peripheral blood and mononuclear cells (PBMCs).
39
PCT/US2020/052805 2019-09-26 2020-09-25 Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same WO2021062212A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080080011.9A CN114746110A (en) 2019-09-26 2020-09-25 Vaccine and immunoglobulin targeting African swine fever virus, and methods of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906357P 2019-09-26 2019-09-26
US62/906,357 2019-09-26

Publications (2)

Publication Number Publication Date
WO2021062212A1 WO2021062212A1 (en) 2021-04-01
WO2021062212A4 true WO2021062212A4 (en) 2021-05-20

Family

ID=75166857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/052805 WO2021062212A1 (en) 2019-09-26 2020-09-25 Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same

Country Status (3)

Country Link
CN (1) CN114746110A (en)
TW (1) TW202126328A (en)
WO (1) WO2021062212A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2275132T3 (en) * 2005-12-29 2021-09-13 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
CN104262484A (en) * 2014-10-17 2015-01-07 深圳出入境检验检疫局动植物检验检疫技术中心 Specific IgY antibody for resisting African swine fever virus as well as preparation method and application thereof
WO2017096341A2 (en) * 2015-12-04 2017-06-08 The Texas A&M University System Adenovirus-vectored multivalent vaccine
WO2018086686A1 (en) * 2016-11-09 2018-05-17 Probiogen Ag Novel porcine cell line for virus production
CN109734810A (en) * 2019-01-24 2019-05-10 深圳市雅臣智能生物工程有限公司 Anti- African swine fever virus and CD dual-target pig source antibody, the preparation method and application
CN110845604B (en) * 2019-11-22 2020-05-26 苏州世诺生物技术有限公司 African swine fever preventing and/or treating neutralizing antibody, preparation method and application thereof

Also Published As

Publication number Publication date
TW202126328A (en) 2021-07-16
CN114746110A (en) 2022-07-12
WO2021062212A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2022013254A (en) Coronavirus vaccine.
Bala et al. The re-emerging of orf virus infection: A call for surveillance, vaccination and effective control measures
Patel et al. Important mammalian veterinary viral immunodiseases and their control
Vogel et al. Early cytokine dysregulation and viral replication are associated with mortality during lethal influenza infection
JP2015178529A5 (en)
RU2554745C2 (en) Recombinant human cc10 protein for treating influenza
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
JPH11501310A (en) Non-toxic immunogens derived from retroviral regulatory proteins, antibodies, methods of manufacture and pharmaceutical compositions comprising them
JP2009529563A5 (en)
Sutherland et al. CD4 and CD8 T cells are not major effectors of mouse hepatitis virus A59-induced demyelinating disease
WO2021062212A4 (en) Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same
Huo et al. Molecular cloning of chicken IL-7 and characterization of its antiviral activity against IBDV in vivo
KR20060129221A (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
MX2022006414A (en) Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowl pox virus.
Castrucci et al. A non-specific defence inducer in preventing clinical signs of infectious bovine rhinotracheitis in calves
US11491197B2 (en) Multiple viral antigen COVID vaccine and therapeutic
US20240181032A1 (en) Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same
US9975945B2 (en) Passive immunisation against influenza, in particular H5N1
JPH07509244A (en) How to prevent shingles or relieve chickenpox-related post-herpetic neuralgia
EP0311651A1 (en) Melatonin-derivatives for psychogenic stress and acute anxiety, and immuno-stimulant drugs
Sahin et al. Potential Neuroinvasion Mechanism of SARS-CoV-2.
Gumkowska-Sroka et al. Immune-mediated inflammatory disease patients in the era of COVID-19—who, how and when to vaccinate against COVID-19
JPH02304100A (en) Interferon for use in prevention or medical treatment of pneumonia or related bacterial desease of pig
CN116139262A (en) Respiratory syncytial virus immune composition and preparation method and application thereof
Huang et al. Protective efficacy of live attenuated rabies virus against Lethal Challenged Virus Strain (CVS-11) infection in the Central Nervous System (CNS) of mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20868864

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20868864

Country of ref document: EP

Kind code of ref document: A1